Status:
TERMINATED
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
Lead Sponsor:
New Mexico Cancer Research Alliance
Conditions:
Non-Hodgkin's Lymphoma
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
1.1 To determine the efficacy of a combination treatment of VP-16, chlorambucil, dexamethasone, and vincristine in patients with relapsed/refractory hematological malignancies. 1.2 To determine the t...
Detailed Description
The purpose of the study is to see how effective the combination of chemotherapy drugs VP-16, chlorambucil, dexamethasone, and vincristine is for patients who have blood cancers that have returned or ...
Eligibility Criteria
Inclusion
- All patients, 18 years of age or older, with Hodgkin's lymphoma, Non-Hodgkin lymphoma (NHL), multiple myeloma (MM), or chronic lymphocytic leukemia (CLL) are eligible.
- Patients must have a life expectancy of at least 12 weeks.
- Patients must have a Zubrod performance status of 0-2.
- Patients must sign an informed consent.
- Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of \> 1,000 or cells/mm3 and platelet count \>50,000/mm3 and absence of a regular red blood cell or platelet transfusion requirement.
- Patients should have adequate hepatic function with a total bilirubin \< 2 mg/dl and SGOT or SGPT \< two times the upper limit of normal, and adequate renal function as defined by a serum creatinine \< 2.0 x upper limit of normal.
- Patients must have received at least two previous chemotherapy regimens for their disease.
- Patients must have measurable disease (NHL) or evaluable disease (MM, CLL).
Exclusion
- Patients with symptomatic brain metastases are excluded from this study.
- Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception.
- Patients may receive no other concurrent chemotherapy or radiation therapy during this trial.
- Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00250718
Start Date
October 1 2004
End Date
May 1 2014
Last Update
August 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States, 87131